申请人:British Biotech Pharmaceuticals Limited
公开号:US06127427A1
公开(公告)日:2000-10-03
Compounds of general formula (I) ##STR1## wherein X ia a --CO.sub.2 H, --NH(OH)CHO or --CONHOH group; R.sub.1 is a cylcoalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one ore more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, cyano (--CN), --CO.sub.2 H, --CO.sub.2 R, --CONH.sub.2, --CONHR, --CON(R).sub.2, --OH, --OR, oxo-, --SH, --SR, --NHCOR, and --NHCO.sub.2 R wherein R is C.sub.1 -C.sub.6 alkyl or benzyl and/or (ii) fused to a cycloalky or heterocyclic ring; and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in specification are matrix metalloproteinase inhibitors.
通式(I)的化合物 ##STR1## 其中X为--CO.sub.2 H, --NH(OH)CHO或--CONHOH基团;R.sub.1为含有最多3个杂原子的环状烷基、环状烯基或非芳香杂环,其中任何一个可能被一个或多个取自C.sub.1-C.sub.6烷基、C.sub.2-C.sub.6烯基、卤素、氰基(--CN)、--CO.sub.2 H、--CO.sub.2 R、--CONH.sub.2、--CONHR、--CON(R).sub.2、--OH、--OR、氧代、--SH、--SR、--NHCOR和--NHCO.sub.2 R的取代基所取代,其中R为C.sub.1-C.sub.6烷基或苄基和/或(ii)与环状烷基或杂环上的环状融合;而R.sub.2、R.sub.3、R.sub.4和R.sub.5如规范中所定义,是基质金属蛋白酶抑制剂。